NCT01106430已完成3 期
A Phase 3b, Double-blind, Randomised, Active-controlled, Parallel Group Study to Assess the Time to Response of Lisdexamfetamine Dimesylate to Atomoxetine Hydrochloride in Children and Adolescents Aged 6-17 Years With Attention-Deficit/Hyperactivity Disorder (ADHD) Who Have Had an Inadequate Response to Methylphenidate Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Shire
- 入组人数
- 267
- 试验地点
- 64
- 主要终点
- Time to First Response
研究概览
简要总结
This study will evaluate how long it takes for ADHD symptoms to improve in subjects who are judged by the Investigator to have had an inadequate response to methylphenidate therapy. The study will also test the safety of Lisdexamfetamine Dimesylate and how well it works.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 6 Years 至 17 Years（Child）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subject has had an historical or current inadequate response to methylphenidate (MPH) treatment. Inadequate response includes but is not limited to the presence of some residual symptoms, with associated impairment inadequate duration of action and/or variability of symptom control, and/or Investigator feels that the subject may derive benefit from an alternative drug treatment to MPH therapy.
- •Subject is a male or female aged 6-17 years inclusive at the time of consent
- •Subject must meet Diagnostic and Statistical Manual of Mental Disorders, fourth edition. - Text Revision (DSM IV TR) criteria for a primary diagnosis of ADHD based on a detailed psychiatric evaluation
- •Subject must have a baseline ADHD-RS-IV total score 28.
排除标准
- •Subject has taken more than 1 MPH treatment (for example, 2 or more different MPH treatments). Examples include but are not limited to RITALIN immediate release (IR) and EQUASYM IR; MEDIKINET IR and CONCERTA; RITALIN long-acting LA and CONCERTA. Note: this does not include subjects who have taken IR MPH for dose titration on a short-term basis (for example, £4 weeks) with an adequate response
- •In the Investigator's judgement, subject has failed to respond to more than 1 previous course(s) of MPH treatment. Failure to respond includes worsening of symptoms or no change/minimal improvement of symptoms.
- •Subject has previously been exposed to STRATTERA or to amphetamine therapy
- •Subject has previously demonstrated intolerable side effects to 1 MPH treatment which limited titration to acceptable efficacy or that required a decrease in dose resulting in unacceptable tolerability and/or efficacy
- •Subject has a current, controlled (requiring a restricted medication) or uncontrolled, comorbid psychiatric diagnosis with significant symptoms such as any severe comorbid Axis II disorder or severe Axis I disorder or other symptomatic manifestations, such as agitated states, marked anxiety, or tension that, in the opinion of the examining physician, will contraindicate treatment with SPD489 or STRATTERA or confound efficacy or safety assessments.
- •Subject has a conduct disorder. Oppositional Defiant Disorder is not exclusionary.
研究组 & 干预措施
Lisdexamfetamine Dimesylate
Experimental
干预措施: Lisdexamfetamine Dimesylate (Drug)
Atomoxetine Hydrochloride
Active Comparator
干预措施: Atomoxetine Hydrochloride (Drug)
结局指标
主要结局
Time to First Response
时间窗: 9 weeks
Time to first response was defined as a Clinical Global Impression-Improvement (CGI-I) value of 1 (very much improved) or 2 (much improved) first recorded following first dose of investigational product. CGI-I consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse).
次要结局
- Change From Baseline in the Weiss Functional Impairment Rating Scale - Parent Report (WFIRS-P) Global Score at Up to 9 Weeks(Baseline and up to 9 weeks)
- Percent of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores - Last Observation Carried Forward (LOCF)(9 weeks)
- Columbia-Suicide Severity Rating Scale (C-SSRS)(9 weeks)
- Udvalg for Kliniske Undersogelser Side Effect Rating Scale - Clinician (UKU-SERS-Clin) With Side Effects Scores >=1(9 weeks)
- Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-Fourth Edition (ADHD-RS-IV) Total Score at 9 Weeks - LOCF(Baseline and 9 weeks)
- Health Utilities Index-2 (HUI-2) Scores at Up to 9 Weeks(up to 9 weeks)
- Change From Baseline in Brief Psychiatric Rating Scale for Children (BPRS-C) Total Score at Up to 9 Weeks(Baseline and up to 9 weeks)
研究者
研究点 (64)
Loading locations...
相似试验
已完成
不适用
A Novel Device for the Management of ADHDADHDNCT05777785VIZO Specs Ltd108
已完成
4 期
Safety and Efficacy of Switching From a Stimulant Medication to Atomoxetine in Children and Adolescents With ADHDAttention Deficit Hyperactivity DisorderNCT00485875Eli Lilly and Company62
进行中（未招募）
不适用
Attention Deficit Hyperactivity Disorder (ADHD) Prediction of Treatment ResponseAttention Deficit Hyperactivity DisorderNCT03153488Massachusetts General Hospital60
已完成
2 期
Treatment of Adult ADHD With Atomoxetine or Atomoxetine and BusparAttention Deficit Disorder With HyperactivityNCT00174226Pfizer241
已完成
3 期
A Trial Evaluating the Efficacy and Safety of HLD200 in Children With ADHDAttention Deficit Hyperactivity DisorderNCT02255513Ironshore Pharmaceuticals and Development, Inc43